Who are Semaglutide J's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Liraglutide Pen Injector [Victoza], Liraglutide Pen Injector [Saxenda], liraglutide monotherapy, Ozempic®, Liraglutide + Exercise training, Continue GLP/GIP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/semaglutide-j.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Semaglutide J — Competitive Intelligence Brief

Semaglutide J (Semaglutide J) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes, Obesity.

phase 3 GLP-1 receptor agonist GLP-1R Diabetes, Obesity Small molecule Live · refreshed every 30 min

Target snapshot

Semaglutide J (Semaglutide J) — Novo Nordisk A/S. Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Semaglutide J TARGET	Semaglutide J	Novo Nordisk A/S	phase 3	GLP-1 receptor agonist	GLP-1R
Liraglutide Pen Injector [Victoza]	Liraglutide Pen Injector [Victoza]	Imperial College London	marketed	GLP-1 receptor agonist	GLP-1R
Liraglutide Pen Injector [Saxenda]	Liraglutide Pen Injector [Saxenda]	University College, London	marketed	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)
liraglutide monotherapy	liraglutide monotherapy	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	GLP-1 receptor agonist	GLP-1R
Ozempic®	Ozempic®	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	marketed	GLP-1 receptor agonist	GLP-1R (glucagon-like peptide-1 receptor)
Liraglutide + Exercise training	Liraglutide + Exercise training	University of Virginia	marketed	GLP-1 receptor agonist	GLP-1R
Continue GLP/GIP	Continue GLP/GIP	The Cleveland Clinic	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Semaglutide J — Competitive Intelligence Brief. https://druglandscape.com/ci/semaglutide-j. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab